Selective Muscarinic M1 Receptor Agonists for Cognitive Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current muscarinic receptor agonists for treating Alzheimer's disease and schizophrenia exhibit significant side effects due to non-selectivity for M1 receptor, leading to peripheral cholinergic side effects such as nausea, gastrointestinal issues, and bradycardia, while existing treatments for pain management have limitations in targeting muscarinic receptors effectively.
Innovation Solution
Development of novel amide compounds that act as highly selective muscarinic M1 receptor agonists, reducing scopolamine-induced amnesia and pain by selectively activating the M1 receptor subtype over M2 and M3 receptor subtypes, thereby minimizing peripheral side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective muscarinic receptor antagonists are used to treat cognitive disorders, then cognitive function can be improved, but peripheral cholinergic side effects such as nausea, gastrointestinal issues, and bradycardia occur
Solution Approach 1:
The patent applies local quality by creating M1-selective compounds that exert their pharmacological action specifically at M1 receptors in the central nervous system, rather than acting non-selectively at all muscarinic receptor subtypes. This selective localization of action at the M1 receptor subtype in the brain enables cognitive improvement without activating peripheral cholinergic pathways that cause gastrointestinal and cardiac side effects.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of muscarinic receptor ligands to alter their receptor subtype selectivity. Through systematic modification of molecular parameters (substituent groups, stereochemistry, and molecular size), the compounds achieve high M1-selectivity over M2, M3, and other muscarinic subtypes, thereby changing the pharmacological profile to eliminate peripheral side effects while maintaining central cognitive benefits.
2Object-affected harmful factors
If M1 receptor selectivity is achieved, then peripheral side effects are minimized, but the complexity of compound development increases
Solution Approach 1:
The patent applies segmentation by dividing the muscarinic receptor family into distinct subtypes (M1, M2, M3, M4, M5) and designing compounds that target specific segments (M1) rather than the entire system. This segmentation approach allows for focused structural modifications that achieve selectivity without requiring complete redesign of the entire pharmacological system.
Solution Approach 2:
The patent applies universality by developing a series of compounds that share common structural features enabling M1-selectivity, allowing these compounds to address multiple cognitive disorders (Alzheimer's, Parkinson's, schizophrenia) with a unified pharmacological approach. The multi-functional capability of M1-selective ligands to improve cognition across different disease models reduces the need for disease-specific drug development.
Data Source
AI summary
This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where R1-R5, X1, X2 and p are as defined herein.